----

----

**FORM      10-QSB**

| x      | QUARTERLY                REPORT UNDER SECTION 13 OR 15(d) OF                THE SECURITIES EXCHANGE ACT OF 1934 For                the quarter ended **April                30, 2007**         |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                |
|  ̈ | TRANSITION                REPORT UNDER SECTION 13 OR 15 (d)OF                THE SECURITIES EXCHANGE ACT OF 1934 For                the transition period from                _______to_______ |

**333-57946**

**INHIBITON      THERAPEUTICS, INC.**

| **Nevada**                                     | **88-0448626**                     |
|------------------------------------------------|------------------------------------|
| (State                or other jurisdiction of | (IRS                Employer       |
| incorporation                or organization)  | Identification                No.) |

**7315      East Peakview Avenue**

**Englewood,      Colorado 80111**

**(303)      796-8940**

----

----

**INHIBITON      THERAPEUTICS, INC.**

**(A      Development Stage Company)**

**Index      to Financial Statements**

**(Unaudited)**

|                                                                              |                                                                                               | **Page** |
|-----------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|----------|
|                                                                              |                                                                                               |     |
| Balance                Sheet at April 30, 2007                                    | F-2                                                                                                |
|                                                                              |                                                                                               |     |
| Statement                of Operations for the three months ended April 30, 2007, |                                                                                               |
|                                                                              | three                months ended April 30, 2006, and from May 11, 2004 (Inception)                |     |
|                                                                              | through                April 30, 2007                                                              | F-3      |
|                                                                              |                                                                                               |     |
| Statement                of Changes in Shareholders' Deficit for the period from  |                                                                                               |
|                                                                              | May                11, 2004 (Inception) through April 30, 2007                                     | F-4      |
|                                                                              |                                                                                               |     |
| Statement                of Cash Flows for the three months ended April 30, 2007, |                                                                                               |
|                                                                              | three                months ended April 30, 2007, and from May 11, 2004                (Inception) |     |
|                                                                              | through                April 30, 2007                                                              | F-5      |
|                                                                              |                                                                                               |     |
| Notes                to Financial Statements                                      | F-6                                                                                                |

----

**INHIBITON      THERAPEUTICS, INC.**

**(A      Development Stage Company)**

**Balance      Sheet**

**April      30, 2007**

**(Unaudited)**

| **Assets**                                                                    |   |    |       |
|-------------------------------------------------------------------------------|--------|--------------|------------|
|  Cash                                                                    |   | $            | 852        |   |
|                                                                          |   |         |       |   |
| Total                  assets                                            |   | $            | 852        |   |
|                                                                          |   |         |       |   |
| **Liabilities                  and Shareholders’ Deficit**              |   |         |       |   |
| Current                  liabilities:                                         |   |         |       |   |
| Accounts                  and notes payable:                                  |   |         |       |   |
| Accounts                  payable, related party (Note 2)                     |   | $            | 286,125    |   |
| Accounts                  payable, other                                      |   |         | 232,449    |   |
| Notes                  payable, related party (Note 2)                        |   |         | 439,430    |   |
| Notes                  payable, other (Note 3)                                |   |         | 30,000     |   |
| Convertible                  notes payable (Note 3)                           |   |         | 100,000    |   |
| Accrued                  interest payable:                                    |   |         |       |   |
| Notes                  payable, related party (Note 2)                        |   |         | 26,888     |   |
| Notes                  payable, other (Note 4)                                |   |         | 5,102      |   |
| Convertible                  notes (Note 3)                                   |   |         | 20,734     |   |
|                                                                          |   |         |       |   |
| Total                  current liabilities                               |   |         | 1,140,728  |   |
|                                                                          |   |         |       |   |
| Commitments                  and contingencies                                |   |         | —    |   |
|                                                                          |   |         |       |   |
| Shareholders’                  deficit:                                 |   |         |       |   |
| Preferred                  stock, $.01 par value; 100,000 shares authorized,  |   |         |       |   |
| -0-                  shares issued and outstanding                            |   |         | —    |   |
| Common                  stock, $.001 par value; 50,000,000 shares authorized, |   |         |       |   |
| 14,895,356                  shares issued and outstanding                     |   |         | 14,895     |   |
| Additional                  paid-in capital                                   |   |         | 928,180    |   |
| Deficit                  accumulated during the development stage             |   |         | (2,082,951 | ) |
|                                                                          |   |         |       |   |
| Total                  shareholders' deficit                             |   |         | (1,139,876 | ) |
|                                                                          |   |         |       |   |
| Total                  liabilities and shareholders' deficit             |   | $            | 852        |   |

----

**INHIBITON      THERAPEUTICS, INC.**

**(A      Development Stage Company)**

**Condensed      Statements of Operations**

**(Unaudited)**

|                                                          |   |                               |       |                              |   | **May                  11, 2004** |   |
|---------------------------------------------------------------|--------|-----------------------------------------|------------|-----------------------------------|--------|-----------------------------------|--------|
|                                                          |   |  **Three                  months** |       | **Three                  months** |   | **(Inception)**                   |   |
|                                                          |   |  **ended**                         |       | **ended**                         |   | **Through**                       |   |
|                                                          |   |  **April                  30,**    |       | **April                  30,**    |   | **April                  30,**    |   |
|                                                          |   |  **2007**                          |       | **2006**                          |   | **2007**                          |   |
|                                                          |   |                               |       |                              |   |                              |   |
| Operating                  costs and expenses:                |   |                                    |            |                              |   |                                   |   |   |   |   |
| Research                  and development                     |   | $                                       | 75,000     |                              | $      | 75,000                            |   | $ | 825,000 |   |
| Selling,                  general and administrative expenses |   |                                    |       |                              |   |                              |   |   |   |   |
| Related                  party (Note 2)                       |   |                                    | 32,250     |                              |   | 32,250                            |   |   | 685,925 |   |
| Other                  (net of stock based compensation)      |   |                                    | 65,613     |                              |   | 4,407                             |   |   | 288,107 |   |
| Stock                  based compensation                     |   |                                    | -          |                              |   | -                                 |   |   | 1,000 |   |
|                                                          |   |                                    |       |                              |   |                              |   |   |   |   |
| Total                  operating costs and expenses      |   |                                    | (172,863   | )                                 |   | (111,657                          | )      |   | (1,800,032 | ) |
|                                                          |   |                                    |       |                              |   |                              |   |   |   |   |
| Interest                  income (Note 3)                     |   |                                    | -          |                              |   | -                                 |   |   | 80,183 |   |
| Interest                  expense (Notes 2, 3 & 4)        |   |                                    | (184,250   | )                                 |   | (15,640                           | )      |   | (363,102 | ) |
|                                                          |   |                                    |       |                              |   |                              |   |   |   |   |
| Loss                  before income taxes                |   |                                    | (357,113   | )                                 |   | (127,297                          | )      |   | (2,082,951 | ) |
|                                                          |   |                                    |       |                              |   |                              |   |   |   |   |
| Income                  tax provision (Note 5)                |   |                                    | -          |                              |   | -                                 |   |   | - |   |
|                                                          |   |                                    |       |                              |   |                              |   |   |   |   |
| Net                  loss                                |   | $                                       | (357,113   | )                                 | $      | (127,297                          | )      | $ | (2,082,951 | ) |
|                                                          |   |                                    |       |                              |   |                              |   |   |   |   |
| Basic                  and diluted loss per common share      |   | $                                       | (0.02      | )                                 | $      | (0.01                             | )      |   |   |   |
|                                                          |   |                                    |       |                              |   |                              |   |   |   |   |
| Weighted                  average common shares outstanding   |   |                                    | 14,463,904 |                              |   | 13,451,000                        |   |   |   |   |

----

**INHIBITON      THERAPEUTICS, INC.**

**(A      Development Stage Company)**

**Condensed      Statement of Changes in Shareholders’ Deficit**

**(Unaudited)**

|                                                          |   |                              |          |                            |   |                                   |   |                                        |                |      |   |
|---------------------------------------------------------------|--------|-----------------------------------|---------------|---------------------------------|--------|----------------------------------------|--------|----------------------------------------|---------------------|-----------|--------|
|                                                          |   |                              |          |                            |   |                                   |   |                                        |                |      |   |
|                                                          |   | **Common                  Stock** |          | ** ****Additional**paid-in |   | **Deficit**accumulated during the |   |                                   |                |
|                                                          |   | **Shares**                        |          | **Par                  value**  |   | **capital**                            |   | **development                  stage** |                | **Total** |   |
| Balance                  at May 11, 2004                      |   |                              |          |                            |   |                                   |   |                                   |                |      |   |   |   |   |   |   |
| Inception                  date                               |   |                              | —       |                            | $      | —                                |   | $                                      | —             |      | $      | — |   | $ | — |   |
|                                                          |   |                              |          |                            |   |                                   |   |                                   |                |      |   |   |   |   |   |   |
| October                  2004 and January 2005,               |   |                              |          |                            |   |                                   |   |                                   |                |      |   |   |   |   |   |   |
| sale                  of common stock                         |   |                              | 9,555,100     |                            |   | 9,555                                  |   |                                   | 269,945             |      |   | — |   |   | 279,500 |   |
| October                  2004, issuance of common stock       |   |                              |          |                            |   |                                   |   |                                   |                |      |   |   |   |   |   |   |
| for                  debt issue costs                         |   |                              | 963,000       |                            |   | 963                                    |   |                                   | (63                 | )         |   | — |   |   | 900 |   |
| December                  2004, issuance of common stock      |   |                              |          |                            |   |                                   |   |                                   |                |      |   |   |   |   |   |   |
| for                  services                                 |   |                              | 107,000       |                            |   | 107                                    |   |                                   | 893                 |      |   | — |   |   | 1,000 |   |
| January                  2005, conversion of notes payable to |   |                              |          |                            |   |                                   |   |                                   |                |      |   |   |   |   |   |   |
| common                  stock                                 |   |                              | 74,900        |                            |   | 75                                     |   |                                   | 625                 |      |   | — |   |   | 700 |   |
| Net                  loss                                     |   |                              | —       |                            |   | —                                |   |                                   | —             |      |   | (534,619 | ) |   | (534,619 | ) |
| Balance                  at January 31, 2005                  |   |                              | 10,700,000    |                            |   | 10,700                                 |   |                                   | 271,400             |      |   | (534,619 | ) |   | (252,519 | ) |
|                                                          |   |                              |          |                            |   |                                   |   |                                   |                |      |   |   |   |   |   |   |
| February                  2005 and March 2005,                |   |                              |          |                            |   |                                   |   |                                   |                |      |   |   |   |   |   |   |
| sale                  of common stock                         |   |                              | 428,000       |                            |   | 428                                    |   |                                   | 99,572              |      |   | — |   |   | 100,000 |   |
| May                  2005 Reverse acquisition of Organic      |   |                              |          |                            |   |                                   |   |                                   |                |      |   |   |   |   |   |   |
| Soils.com,                  Inc.                              |   |                              | 2,323,000     |                            |   | 2,323                                  |   |                                   | (47,179             | )         |   |   |   |   | (44,856 | ) |
| Net                  loss                                     |   |                              | —       |                            |   | —                                |   |                                   | —             |      |   | (664,190 | ) |   | (664,190 | ) |
|                                                          |   |                              |          |                            |   |                                   |   |                                   |                |      |   |   |   |   |   |   |
| Balance                  at January 31, 2006                  |   |                              | 13,451,000    |                            |   | 13,451                                 |   |                                   | 323,793             |      |   | (1,198,809 | ) |   | (861,565 | ) |
|                                                          |   |                              |          |                            |   |                                   |   |                                   |                |      |   |   |   |   |   |   |
| July                  2006 and August 2006,                   |   |                              |          |                            |   |                                   |   |                                   |                |      |   |   |   |   |   |   |
| sale                  of common stock, less                   |   |                              |          |                            |   |                                   |   |                                   |                |      |   |   |   |   |   |   |
| $7,500                  of offering costs                     |   |                              | 250,000       |                            |   | 250                                    |   |                                   | 67,250              |      |   | — |   |   | 67,500 |   |
| Net                  loss                                     |   |                              |  — |                            |   | —                                |   |                                   | —             |      |   | (527,029 | ) |   | (527,029 | ) |
|                                                          |   |                              |          |                            |   |                                   |   |                                   |                |      |   |   |   |   |   |   |
| Balance                  at January 31, 2007                  |   |                              | 13,701,000    |                            |   | 13,701                                 |   |                                   | 391,043             |      |   | (1,725,838 | ) |   | (1,321,094 | ) |
|                                                          |   |                              |          |                            |   |                                   |   |                                   |                |      |   |   |   |   |   |   |
| March                  2007, conversion of                    |   |                              |          |                            |   |                                   |   |                                   |                |      |   |   |   |   |   |   |
| convertible                  promissory notes to              |   |                              |          |                            |   |                                   |   |                                   |                |      |   |   |   |   |   |   |
| common                  stock (Note 3)                        |   |                              | 594,356       |                            |   | 594                                    |   |                                   | 213,374             |      |   | — |   |   | 213,968 |   |
| Issuance                  of warrants upon conversion         |   |                              |          |                            |   |                                   |   |                                   |                |      |   |   |   |   |   |   |
| of                  convertible promissory notes (Note 3)     |   |                              | —       |                            |   | —                                |   |                                   | 172,363             |      |   | — |   |   | 172,363 |   |
| March                  2007, sale of common stock             |   |                              |          |                            |   |                                   |   |                                   |                |      |   |   |   |   |   |   |
| (Note                  6)                                     |   |                              | 500,000       |                            |   | 500                                    |   |                                   | 124,500             |      |   | — |   |   | 125,000 |   |
| April                  2007, sale of common stock,            |   |                              |          |                            |   |                                   |   |                                   |                |      |   |   |   |   |   |   |
| less                  $3,000 of offering costs (Note 6)       |   |                              | 100,000       |                            |   | 100                                    |   |                                   | 26,900              |      |   | — |   |   | 27,000 |   |
| Net                  loss                                     |   |                              | —       |                            |   |    —              |   |                                   |  —  |      |   | (357,113 | ) |   | (357,113 | ) |
|                                                          |   |                              |          |                            |   |                                   |   |                                   |                |      |   |   |   |   |   |   |
| Balance                  at April 30, 2007                    |   |                              | 14,895,356    |                            | $      | 14,895                                 |   | $                                      | 928,180             |      | $      | (2,082,951 | ) | $ | (1,139,876 | ) |

----

**INHIBITON      THERAPEUTICS, INC.**

**(A      Development Stage Company)**

**Condensed      Statements of Cash Flows**

**(Unaudited)**

|                                                                |   |                               |     |                              |   | **May                  11, 2004** |   |
|---------------------------------------------------------------------|--------|-----------------------------------------|----------|-----------------------------------|--------|-----------------------------------|--------|
|                                                                |   |  **Three                  months** |     | **Three                  months** |   | **(Inception)**                   |   |
|                                                                |   |  **ended**                         |     | **ended**                         |   | **Through**                       |   |
|                                                                |   |  **April                  30,**    |     | **April                  30,**    |   | **April                  30,**    |   |
|                                                                |   |  **2007**                          |     | **2006**                          |   | **2007**                          |   |
|                                                                |   |                               |     |                              |   |                              |   |
| Cash                  flows from operating activities:              |   |                                    |     |                              |   |                              |   |   |   |   |
| Net                  loss                                           |   | $                                       | (357,113 | )                                 | $      | (127,297                          | )      | $ | (2,082,951 | ) |
| Adjustments                  to reconcile net loss to net cash      |   |                                    |     |                              |   |                              |   |   |   |   |
| used                  by operating activities:                      |   |                                    |     |                              |   |                              |   |   |   |   |
| Stock                  based compensation                           |   |                                    | —  |                              |   | —                           |   |   | 1,000 |   |
| Loss                  on debt extinguishment (Note 3)               |   |                                    | 65,379   |                              |   | —                           |   |   | 65,379 |   |
| Expense                  incurred upon issuance or modification     |   |                                    |     |                              |   |                              |   |   |   |   |
| of                  stock and warrants (Note 3)                     |   |                                    | 172,363  |                              |   | —                           |   |   | 172,363 |   |
| Changes                  in operating assets and liabilities:       |   |                                    |     |                              |   |                              |   |   |   |   |
| Prepaid                  expense                                    |   |                                    | —  |                              |   | —                           |   |   | — |   |
| Accounts                  payable                                   |   |                                    | 307      |                              |   | 16,459                            |   |   | 232,248 |   |
| Related                  party payables (Note 2)                    |   |                                    | 27,250   |                              |   | 32,250                            |   |   | 286,125 |   |
| Accrued                  expenses                                   |   |                                    | (2,427   | )                                 |   | 11,859                            |   |   | 76,514 |   |
| Net                  cash used in                              |   |                                    |     |                              |   |                              |   |   |   |   |
|  operating                  activities                         |   |                                    | (94,241  | )                                 |   | (66,729                           | )      |   | (1,249,322 | ) |
|                                                                |   |                                    |     |                              |   |                              |   |   |   |   |
| Cash                  flows from investing activities:              |   |                                    |     |                              |   |                              |   |   |   |   |
| Investment                  in Inhibitex Therapeutics, Inc.         |   |                                    | —  |                              |   | —                           |   |   | (44,856 | ) |
| Net                  cash used in                              |   |                                    |     |                              |   |                              |   |   |   |   |
|  investing                  activities                         |   |                                    | —  |                              |   | —                           |   |   | (44,856 | ) |
|                                                                |   |                                    |     |                              |   |                              |   |   |   |   |
| Cash                  flows from financing activities:              |   |                                    |     |                              |   |                              |   |   |   |   |
| (Payments                  on) proceeds from related party notes    |   |                                    |     |                              |   |                              |   |   |   |   |
| payable,                  net (Note 2)                              |   |                                    | (57,048  | )                                 |   | 66,282                            |   |   | 428,030 |   |
| Proceeds                  from notes payable, other                 |   |                                    | —  |                              |   | —                           |   |   | 43,000 |   |
| Proceeds                  from convertible promissory note (Note 3) |   |                                    | —  |                              |   | —                           |   |   | 225,000 |   |
| Proceeds                  from issuance of common stock,            |   |                                    |     |                              |   |                              |   |   |   |   |
| net                  of offering costs (Note 6)                     |   |                                    | 152,000  |                              |   | —                           |   |   | 599,000 |   |
| Net                  cash provided by                          |   |                                    |     |                              |   |                              |   |   |   |   |
|  financing                  activities                         |   |                                    | 94,952   |                              |   | 66,282                            |   |   | 1,295,030 |   |
|                                                                |   |                                    |     |                              |   |                              |   |   |   |   |
| Net                  change in cash and                        |   |                                    |     |                              |   |                              |   |   |   |   |
|  cash                  equivalents                             |   |                                    | 711      |                              |   | (447                              | )      |   | 852 |   |
|                                                                |   |                                    |     |                              |   |                              |   |   |   |   |
| Cash                  and cash equivalents:                         |   |                                    |     |                              |   |                              |   |   |   |   |
| Beginning                  of period                                |   |                                    | 141      |                              |   | 747                               |   |   | — |   |
|                                                                |   |                                    |     |                              |   |                              |   |   |   |   |
| End                  of period                                      |   | $                                       | 852      |                              | $      | 300                               |   | $ | 852 |   |
|                                                                |   |                                    |     |                              |   |                              |   |   |   |   |
| Supplemental                  disclosure of cash flow information:  |   |                                    |     |                              |   |                              |   |   |   |   |
| Cash                  paid during the period for:                   |   |                                    |     |                              |   |                              |   |   |   |   |
| Income                  taxes                                       |   | $                                       | —  |                              | $      | —                           |   | $ | — |   |
| Interest                                                            |   | $                                       | 9,614    |                              | $      | 36,954                            |   | $ | 52,006 |   |
|                                                                |   |                                    |     |                              |   |                              |   |   |   |   |
| Noncash                  financing transactions:                    |   |                                    |     |                              |   |                              |   |   |   |   |
| Notes                  and interest payable converted to stock      |   | $                                       | 148,589  |                              | $      | —                           |   | $ | 149,289 |   |
| Stock                  issued in exchange for debt issue costs      |   | $                                       | —  |                              | $      | —                           |   | $ | 900 |   |

----

**INHIBITON              THERAPEUTICS, INC.**

**(A              Development Stage Company)**

**Notes              to Condensed Financial Statements**

**(Unaudited)**

**Note      1: **
**Basis      of presentation**

**Reorganization**

----

**INHIBITON            THERAPEUTICS, INC.**

**(A            Development Stage Company)**

**Notes            to Condensed Financial Statements**

**(Unaudited)**

**Derivative      Instruments**

**Note      2: **
**Related      Party**

| Management                fees payable to officers              |   | $      | 259,500 |   |
|-----------------------------------------------------------------|--------|--------|---------|--------|
|                                                            |   |   |    |   |
| Rent                payable to company affiliated with officers |   |   | 26,625  |   |
|                                                            |   |   |    |   |
| Total                accounts payable, related party            |   | $      | 286,125 |   |

----

**INHIBITON          THERAPEUTICS, INC.**

**(A          Development Stage Company)**

**Notes          to Condensed Financial Statements**

**(Unaudited)**

| Notes                payable to officers; interest at 8% and due on demand                                                     |   | $      | 10,313  |   |
|--------------------------------------------------------------------------------------------------------------------------------|--------|--------|---------|--------|
|                                                                                                                           |   |   |    |   |
| Notes                payable to affiliates of Company officers; interest at 8% and due                on                demand |   |   | 416,117 |   |
|                                                                                                                           |   |   |    |   |
| Note                payable to significant stockholder; interest at 8% and due on                demand                        |   |   | 13,000  |   |
|                                                                                                                           |   |   |    |   |
| Notes                payable, related party                                                                                    |   |   | 439,430 |   |
|                                                                                                                           |   |   |    |   |
| Interest                payable related party                                                                                  |   |   | 26,888  |   |
|                                                                                                                           |   |   |    |   |
| Total                principal and interest payable, related party                                                             |   | $      | 466,318 |   |

----

**INHIBITON            THERAPEUTICS, INC.**

**(A            Development Stage Company)**

**Notes            to Condensed Financial Statements**

**(Unaudited)**

**Note      3: **
**Convertible      Notes Payable**

----

**INHIBITON            THERAPEUTICS, INC.**

**(A            Development Stage Company)**

**Notes            to Condensed Financial Statements**

**(Unaudited)**

**Note      4: **
**Notes      Payable**

**Note      5: **
**Income      Tax**

**Note      6: **
**Capital      Stock**

----

**INHIBITON          THERAPEUTICS, INC.**

**(A          Development Stage Company)**

**Notes          to Condensed Financial Statements**

**(Unaudited)**

----

**INHIBITON            THERAPEUTICS, INC.**

**(A            Development Stage Company)**

**Notes            to Condensed Financial Statements**

**(Unaudited)**

**Item      2. Plan of Operation**

----

**.**

**Item      3. Controls and Procedures**

**PART      II - OTHER INFORMATION**

**Item      1. Legal Proceedings**

**Item      2. Unregistered Sales of Equity Securities**

----

**Item      3. Defaults upon Senior Securities**

**Item      4. Submission of Matters to a Vote of Security Holders**

**Item      5. Other Information**

**Item      6. Exhibits**

| **Exhibits:** |                                                                                                      |
|---------------|-----------------------------------------------------------------------------------------------------------|
| 31.1          | CEO                Certification pursuant to Section 302 of the Sarbanes-Oxley Act of                2002 |
| 32.1          | CEO                Certification pursuant to Section 906 of the Sarbanes-Oxley Act of                2002 |

----

|   | **INHIBITON                THERAPEUTICS, INC.** |
|--------|-------------------------------------------------|
|   | (Registrant)                                    |

| Date:                June                14, 2007 | By:                /s/                Henry Fong                                               |
|---------------------------------------------------|------------------------------------------------------------------------------------------------|
|                                              | Henry                Fong                                                                      |
|                                              | Principal                Executive Officer andPrincipal Accounting                Officer |
|                                              |                                                                                           |